This modified branching Tat peptide was used to label LPs loaded with doxorubicin, leading to decreased non-specific uptake and increased uptake by tumor cells, resulting in increase in anti-tumor activity and decrease in systemic side effects [118]. Here, TAT is linked to neoplasm.